Cefuroxime versus cefazolin as prophylaxis in vascular surgery

Area of Science:

• Infectious Diseases
• Surgical Infections
• Pharmacology

Background:

• * Staphylococcus aureus wound infections remain a complication in vascular surgery despite cefazolin prophylaxis.
• * Cefazolin's susceptibility to beta-lactamase may contribute to prophylaxis failures in cardiac surgery.

Purpose of the Study:

• * To investigate if a more beta-lactamase-stable cephalosporin, cefuroxime, reduces vascular wound infections compared to cefazolin.
• * To compare the efficacy of cefuroxime and cefazolin in preventing postoperative wound infections in vascular surgery.

Main Methods:

• * Prospective, randomized trial comparing cefuroxime and cefazolin prophylaxis.
• * Standardized dosing regimens for both antibiotics, including intraoperative and postoperative administration.
• * In vitro susceptibility testing of Staphylococcus aureus isolates.

Main Results:

• * No significant difference in deep wound infection rates between cefuroxime (2.6%) and cefazolin (1.0%) recipients (p = 0.2).
• * Staphylococcus aureus wound infections occurred in five cefuroxime versus two cefazolin recipients.
• * In vitro studies showed greater susceptibility of S. aureus to cefazolin (MIC 0.5 µg/ml) than cefuroxime (MIC 2.0 µg/ml).
• * Cefuroxime exhibited lower trough serum concentrations than cefazolin, and longer procedures were associated with infection in cefuroxime recipients.

Conclusions:

• * Cefuroxime did not demonstrate superior efficacy over cefazolin in reducing vascular surgical wound infections.
• * Lower serum concentrations and in vitro susceptibility patterns suggest cefazolin may be more effective in this setting.
• * Antibiotic tissue concentrations and procedure length may influence infection risk in vascular surgery.